Abstract
The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [ San Francisco, US; July 1995 ].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
